

Edgar Filing: CELLPOINT INC - Form 10QSB

CELLPOINT INC
Form 10QSB
February 14, 2002

U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 10-QSB

(MARK ONE)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2001

OR

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM _____ TO _____

COMMISSION FILE NUMBER 000-25205

CELLPOINT INC.

(Name of small business issuer in its charter)

NEVADA
(State or other jurisdiction of
incorporation or organization)

52-2032380
(I.R.S. Employer
Identification No.)

3000 HILLSWOOD DRIVE,
HILLSWOOD BUSINESS PARK,
CHERTSEY, SURREY KT16 ORS, ENGLAND
(Address of principal executive offices)

(Zip Code)

44-1932 895 310
(Issuer's telephone number, including area code)

Securities registered under Section 12(b) of the Exchange Act: NONE.
Securities registered under Section 12(g) of the Exchange Act:

TITLE OF EACH CLASS

NAME OF EACH EXCHANGE
ON WHICH REGISTERED

Edgar Filing: CELLPOINT INC - Form 10QSB

Common Stock, \$.001 par value

NASDAQ National Market

Check whether the issuer: (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for past 90 days. Yes No

(ISSUERS INVOLVED IN BANKRUPTCY PROCEEDING DURING THE PAST FIVE YEARS)

Check whether the issuer has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Exchange Act after the distribution of securities under a plan confirmed by a court. Yes No

(APPLICABLE ONLY TO CORPORATE REGISTRANTS)

State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date: As of January 17, 2002, 16,355,543 shares of Common Stock, par value \$.001 per share.

Transitional Small Business Disclosure Format (check one): Yes No

=====
PART I
FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

The financial statements for the Company's second fiscal quarter ended December 31, 2001 are attached to this Report, commencing on page F-1.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our consolidated financial condition and consolidated results of operations should be read in conjunction with our consolidated financial statements and related notes thereto in our Annual Report on Form 10-KSB for the fiscal year ended June 30, 2001.

RECENT DEVELOPMENTS

UNWIRE AB AND TELEMATICS OPERATIONS IN CELLPOINT SOUTH AFRICA

On May 19, 2001, the Company approved the disposal of the telematics business segment of the Company and committed to a plan to dispose of the business. Accordingly, the telematics business segment was presented as a discontinued operation in the balance sheet as of June 30, 2001 and the related statements of operations and cash flows for the six months ended December 31, 2001. At June 30, 2001, the Company had accrued approximately \$1,100,000 for additional losses expected from the discontinued operations through the expected date of disposition. For the six months ended December 31, 2001 the Company has incurred losses of approximately \$1,085,000 against the accrual. The Company does not anticipate any further significant losses in connection with the disposal of this segment and the segment is no longer a part of the Company. Net

Edgar Filing: CELLPOINT INC - Form 10QSB

sales for Telematics were approximately \$264,000 and \$195,037 for the six months ended December 31, 2001 and 2000, respectively.

On October 9, 2001, the Company's subsidiary, Unwire AB, filed for protection under the bankruptcy courts in Sweden. As a result of the filing, the Company has ceased all funding of Unwire operations. The bankruptcy courts have appointed a Trustee to oversee the disbursement of Unwire's assets and the Company now has no control over the operations or decision making capabilities of Unwire. As a result, Unwire is no longer included in the consolidated financial statements of the Company.

In November, 2001 CellPoint Systems SA ("Systems SA"), the Company's South African subsidiary, filed for liquidation under the laws of South Africa. Systems SA operated a research and development facility for the Company. The telematics portion of Systems SA has already been included in the discontinued operations for financial reporting

purposes. The results of the location services portion of Systems SA is not included in discontinued operations, and those functions are to be continued within the Company's Swedish operating subsidiary. Costs of closing this subsidiary, primarily the write-off of the net receivable from Systems SA, were accrued in the June 30, 2001 financial statements.

RESTRUCTURING PROGRAM

On October 19, 2001 CellPoint Systems AB acquired 100% of its partly-owned development company, Micronet MLS AB in Karlskrona, Sweden, purchasing the outstanding 42% of Micronet MLS and assets with 107,142 shares of the Company's common stock. Micronet MLS AB staff have transferred to Systems AB to preserve the security of the Company's technology and facilitate cost savings in the future.

As a result of the above, Micronet MLS AB is currently a dormant entity and is expected to be liquidated in the near future.

Consistent with the Company's strategy to reduce operating costs within continuing operations, the United Kingdom subsidiary CellPoint Europe Ltd filed for liquidation on November 2, 2001. The Company's headquarters and management functions reside in its office in Kista, Sweden. A branch office will be maintained in the United Kingdom to continue serving existing and future customers.

LONG TERM DEBT

On December 6, 2000, the Company entered into an agreement whereby it issued to Castle Creek Technology Partners LLC ("Castle Creek") convertible notes in the aggregate principal amount of \$10,000,000, which were originally due and payable on September 30, 2002. Interest on the debt is 6% per annum, compounded semi-annually and payable semi-annually on each June 30 and December 31. Prior to June 5, 2001, the notes were convertible, in whole or in part, at a fixed conversion price of \$25 per share at the option of the holder of the debt and could be converted in exchange for all or part of the outstanding debt plus the accrued interest at the conversion date. Subsequent to June 5, 2001, the notes were convertible at the lower of \$25 or 90% of the average of the five lowest volume weighted average prices during the period of twenty consecutive trading days ending on the trading day immediately prior to the date of determination. The conversion of the notes contained certain limitations as set forth in the agreement. The Company has reserved 2,000,000 shares for the purpose of possible future conversions.

Edgar Filing: CELLPOINT INC - Form 10QSB

In connection with the convertible notes, the Company issued a warrant that was immediately exercisable and which expires on December 5, 2005. The warrant grants Castle Creek the right to purchase 210,526 shares of the Company's common stock at an exercise price per share of \$11.40, subject to adjustment.

On July 25, 2001, the Company entered into a note purchase, modification and forbearance agreement with Castle Creek concerning the above mentioned notes. Under the agreement, the outstanding notes were to be repurchased by the Company. The Company agreed to buy back the outstanding principal of the notes over 90 days for 86% of the remaining principal, plus accrued interest, and issued a warrant with 500,000 shares issuable upon exercise of the warrant at an exercise price of \$3.14 per share and exercisable after one year for a period of four years (subject to specified anti-dilution adjustments). In addition, the Company granted to Castle Creek a security interest in its assets (including the assets of its subsidiaries), including its intellectual property. Castle Creek agreed not to trade in the Company's stock effective July 25, 2001 until the note repurchase is completed, in consideration for which Castle Creek was paid \$1,000,000 as a non-refundable deposit against the final note purchase payment. The fixed conversion price of the Notes was changed to \$4.00 with no floating conversion price if the notes are purchased on a timely basis and the Company complies with all its other obligations to Castle Creek in all material respects. The Company also agreed to certain limitations on the terms of future debt and equity financings, which limitations would not apply to a financing that provided the proceeds for the final purchase of the Notes.

On September 26, 2001, the Company and Castle Creek entered into an amendment of the July 25, 2001 agreement, wherein the outstanding convertible notes were to be repurchased at 100% of the remaining principal and subject to a fixed conversion price of \$4.00. The Company paid \$2,250,000 to Castle Creek on September 26, 2001 for principal and accrued interest and was scheduled to make a final payment on October 1, 2002 for \$6,105,100 plus accrued interest (subject to specified adjustments upon a material breach by the Company). The outstanding notes are

prepayable in part or in whole at any time without penalty. However, if the Company is in non-compliance of the limitations on the terms of future debt and equity financing, there will be a \$2,000,000 penalty and the notes will become convertible at the lower of 1) the average closing price during the ten day period beginning five days prior to the date of the non-compliance event or (2) the lowest price of common stock or common stock equivalents sold from September 25, 2001 to the non-compliance event. The July agreement, except as modified by the amendment and the Stipulation and Order discussed below, remains in effect.

On November 15, 2001, the Company was served with a suit by Castle Creek, and on December 13, 2001, Castle Creek filed an amended complaint, to have its debt of in excess of \$6.1 million principal plus interest declared due and payable, for a default payment of \$2 million and other damages and relief. The principal issue in dispute in the litigation was the antidilution adjustment applicable to the number of shares that Castle Creek is entitled to purchase under the warrant issued in the July 25, 2001 restructuring with Castle Creek to purchase 500,000 shares of common stock (see "Legal Proceedings").

On December 19, 2001, the Company entered into a Stipulation and Order with Castle Creek providing that Castle Creek agreed to stay prosecution of this case until February 28, 2002, provided that the Company makes required prepayments on its Notes to Castle Creek of \$200,000 by January 31, 2002, which payment was timely made, and an additional \$550,000 by February 28, 2002, and provided, further, that the Company does not breach its agreements and

Edgar Filing: CELLPOINT INC - Form 10QSB

instruments with Castle Creek subsequent to the date of the Stipulation and Order. In addition, the Stipulation and Order specified an adjustment in the exercise price of the December 2000 warrant from \$11.40 to \$7.75 and the July 2001 warrant that carried anti-dilution provisions was amended to give Castle Creek the right to purchase 1,500,000 shares at an adjusted exercise price of \$1.20 per share. There are no further adjustments to the number of shares purchasable under the July 2001 warrant except by reason of stock splits, stock dividends and the like. The July 2001 warrant is immediately exercisable as to 50% of the 1,500,000 shares and exercisable as to the balance beginning July 25, 2002, with the warrant expiring on July 25, 2006. If the Company is in compliance with the provisions of the Stipulation and Order at February 28, 2002, then Castle Creek will dismiss the case with prejudice. The Company is also required to make prepayments of the Notes in an amount equal to 25% of the gross proceeds of each financing the Company closes; provided, that the maximum aggregate amount of prepayments that the Company is required to make under the Stipulation and Order prior to October 1, 2002 (the due date of the Notes) is \$3,000,000.

As of December 31, 2001, Castle Creek had converted \$750,000 of the notes into 270,594 shares.

Following each of the debt modifications, the Company applied the rules of Emerging Issues Task Force ("EITF") 96-19: "Debtor's Accounting for a Modification or Exchange of Debt Instruments." Based on the provisions of EITF 96-19 it was determined that there was not a substantial change from the original debt agreement and as such, the modified debt continues to be presented at fair value using the new effective interest rate. Legal fees associated with the modifications were expensed in the periods in which they were incurred.

Due to the beneficial conversion features associated with the financing, the Company applied EITF 00-27: Application of EITF No. 98-5 "Accounting for Convertible Securities with Beneficial Conversion Features or Contingently Adjustable Conversion Ratios", to the convertible instruments. In accordance with EITF 00-27 the value of the beneficial conversion feature was recorded as a reduction to the carrying amount of the convertible debt and an addition to paid-in-capital. The fair value of the warrants granted in connection with the financing and the amendments thereto was calculated using the Black Scholes pricing model and recorded as a further reduction to the carrying amount and an addition to paid-in-capital.

As a result of the private placements at the end of the first quarter the anti-dilution provision attached to the warrants issued on July 25, 2001 became effective. As such, the Company recalculated and adjusted the exercise price and therefore adjusted the number of shares issuable upon exercise of the warrants. This resulted in an adjusted exercise price of \$1.42 and additional shares of 608,235 issuable upon exercise of the warrants. The adjustment to the exercise price of the warrants increased the value of the warrants recorded as debt discount by \$263,553. The terms of this warrant were further modified by the Stipulation and Order discussed above. As a result of the changes provided by the Stipulation and Order, a further discount of \$248,574 was recorded.

The Company has therefore recorded a total debt discount of approximately \$4,026,000 and is amortizing the discount over the term of the debt. Amortization is accelerated when necessary for conversions and repayments of the debt principal. Amortization for the three and six month periods ended December 31, 2001 and 2000 was approximately \$483,000, \$128,000, \$1,604,000 and \$128,000, respectively, and is recorded as a component of financial items.

On December 20, 2001, the Company negotiated an additional \$500,000

Edgar Filing: CELLPOINT INC - Form 10QSB

loan in addition to the \$4 million loan already outstanding with M&S Trust.

RECENT SALE OF SECURITIES

On September 25, 2001, the Company closed a private placement pursuant to which it issued 3,250,000 shares of Common Stock for proceeds of \$3,250,000. In addition, the Company issued warrants to purchase 1,625,000 shares of Common Stock, exercisable at \$2.25 per share for two years. The Company used part of the proceeds from this offering to make the initial required payment to Castle Creek for the repurchase of a portion of the convertible notes held by Castle Creek.

On September 25, 2001, the Company closed a placement under Regulation S for an aggregate of \$2,071,130, pursuant to which the Company issued an aggregate of 1,568,144 shares and 784,071 warrants to purchase shares of the Company's Common Stock, exercisable at \$2.36 per share for two years.

As a result of the private placements, the Company has received proceeds totaling approximately \$5,762,000 by December 31, 2001. Commitments totaling approximately \$859,000 have been reported as Stock subscriptions receivable in Stockholders' equity. Shares of the Company's Common Stock in relation to the Stock subscription receivable have not been issued and thus they have been reflected in Stockholders' equity as Common Shares to be issued at December 31, 2001.

On October 5, 2001, the Company completed the initial closing of a private placement of Common Stock and warrants pursuant to which it issued an aggregate of 1,238,096 shares of Common Stock for proceeds of \$1,300,000. In addition, the Company issued warrants to purchase 619,048 shares of Common Stock, half of which are exercisable at \$3.50 per share for twelve months following the closing, and the other half of which are exercisable at \$5.00 per share for twenty-four months following the closing.

COMMERCIAL DEVELOPMENTS

On November 26, 2001, CellPoint announced that E-Plus had ordered CellPoint's Mobile Location Broker (MLB) as its location middleware platform. The MLB will be used for external access to location data, empowering Mobile Virtual Network Operators, independent Service Providers, and other partners when creating value added services. MLB is an integral component enabling new revenue streams for mobile operators and their Service Provider partners to deliver location-specific mobile Internet services. CellPoint's Mobile Location Server (MLS) is already installed at E-Plus and can position users irrespective of whether they are actively engaged in a call or not; MLB completes the full solution for location service provision.

During the Quarter, the Company announced results of an extensive performance testing program for its network-based location services platform, Mobile Location System (MLS). Stringent tests were carried out on an entry-level location platform configuration to measure and capture the performance data that is most important to GSM carriers. The CellPoint platform was loaded to simulate 2,500 users doing 504,000 requests over a 60-minute period. This load reflects a capacity of 140 location transactions per second. The Company also announced it was ready to accept challenges by any location platform vendor in any GSM environment.

EVENTS AFTER DECEMBER 31, 2001

On January 31, 2002, the Company closed a private placement of Common Stock and warrants pursuant to which it issued an aggregate of 848,982 shares of Common Stock for proceeds of \$665,000. In addition, the Company issued warrants to purchase 424,471 shares of Common Stock which are exercisable at \$1.50 per

Edgar Filing: CELLPOINT INC - Form 10QSB

share for twenty four months

following the closing.

On January 31, 2002, CellPoint paid \$200,000 to Castle Creek per the Stipulation and Order discussed above.

On February 5, 2002, the Company announced its Mobile Location Broker had been selected and installed for a major European Mobile Portal with further details to be provided before 3GSM World in Cannes, France taking place on Feb 19-21.

RESULTS OF OPERATIONS

THREE MONTHS ENDED DECEMBER 31, 2001

The results of continuing operations are reported herein for the Company's location services business. The Company's telematics division is reported as "discontinued operations".

REVENUES. In the fiscal quarter ended December 31, 2001 (the "Current Quarter"), the Company's gross revenues from continuing operations were \$176,552, as compared to revenues from continuing operations of \$804,417 for the fiscal quarter ended December 31, 2000 (the "Comparable Quarter"). All of the Company's revenues came from the European market. The decrease in revenues is considered to be a timing effect as the Company previously recorded revenue in prior quarters based on revenue recognition rules for software installation of its Mobile Location System (MLS) product. The Company is currently engaged in several negotiations to close further contracts. No revenues were recorded during the quarter from the contract announced in December 2001 for the license sale of its Mobile Location Broker.

COST OF REVENUES. Costs incurred by the Company in producing revenues in the Comparable Quarter were mainly the costs of supplying hardware in conjunction with the sale of the previous generation of software platforms. Such costs decreased by \$112,929 to \$14,637 in the Current Quarter as compared to \$127,566 in the Comparable Quarter. The Company's role in supplying hardware in relation to its sale of software and applications is decreasing, and accordingly, the costs of producing revenue as a percentage of revenue has decreased. Research and development expenses are recorded separately.

GROSS PROFIT. For the Current Quarter, the Company recorded a gross profit of \$161,915 as compared to \$676,851 gross profit in the Comparable Quarter. This decrease in gross profit is attributable to the decrease in revenues in the Current Quarter whilst the gross margin increased by 7.6% to 91.7% in the Current Quarter from 84.1% in the Comparable Quarter as a result of decreased need to supply hardware as part of the Company's product.

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES. The Company's selling, general and administrative expenses decreased by \$1,269,694 to \$599,929 in the Current Quarter from \$1,869,623 in the Comparable Quarter. The decrease in selling, general and administrative expenses in the Company's continuing operations was primarily due the Company's restructuring program. Recurring selling, general and administrative expenses are expected to decrease in future periods due to the restructuring program in place compared to the fiscal year ended June 30, 2000.

RESEARCH AND DEVELOPMENT EXPENSES. The Company's research and development expenses increased by \$298,147 to \$1,388,832 in the Current Quarter from \$1,090,685 in the Comparable Quarter. The increase in research and

Edgar Filing: CELLPOINT INC - Form 10QSB

development expenses in the Company's continuing operations was due to the research and development of the new generation of software platforms for location-based services.

PROFESSIONAL FEES. Professional fees increased by \$24,756 to \$485,585 in the Current Quarter from \$460,829 in the Comparable Quarter due to charges from the Company's previous law firm of at least \$250,000 which, according to the Company, is without merit as following the Company's the lawsuit against the law firm. Professional fees in the Current Quarter are related to costs incurred in connection with general legal, accounting, consulting and regulatory compliance.

DEPRECIATION AND AMORTIZATION EXPENSE. Depreciation and amortization expense increased by \$39,624 to \$974,912 in the Current Quarter from \$935,288 in the Comparable Quarter. Depreciation and amortization is primarily

related to purchased technology. The amortization of the positioning technology acquired in connection with the Unwire acquisition and retained by the continuing operations amounts to \$386,879 and \$386,879 and the amortization of the original core technology amounts to \$445,830 and \$497,082 for the three months ended December 31, 2001 and 2000, respectively.

FINANCIAL ITEMS. Financial items resulted in an expense of \$745,148 in the Current Quarter compared to a net expense of \$599,037 in the Comparable Quarter. Interest expense was \$664,882 in the Current Quarter, compared to interest income of \$198,125 in the Comparable Quarter. The increase in interest expense was attributable to the \$10,000,000 of convertible notes issued in December 2000 and the amortization of the debt discount recorded in relation to those notes and the subsequent amendments to the terms thereof resulting in non-cash expense in the Current Quarter of \$483,305. Interest expense in the Current Quarter consisted of non-cash expense of \$483,305 on the Castle Creek debt discount, interest of \$91,577 to Castle Creek and interest of \$90,000 to M&S Trust. In the Current Quarter, the Company had realized foreign exchange losses aggregating \$125,591 whereas in the Comparable Quarter, the Company had net realized foreign exchange gain of \$6,610. These items result primarily from exchange rate fluctuations in the currencies of the United States, England and Sweden.

LOSS FROM CONTINUING OPERATIONS. Loss from continuing operations for the Current Quarter was (\$4,032,491) versus (\$4,620,896) in the Comparable Quarter. The decrease in loss from continuing operations in the Current Quarter was mainly a result of the restructuring of the Company.

INCOME/LOSS FROM DISCONTINUED OPERATIONS. On July 25, 2001, the Company publicly announced its intention to sell its telematics division. On October 9, 2001, Unwire filed for bankruptcy protection under the laws of Sweden. Under accounting principles generally accepted in the United States, the results of operations for the telematics division, are presented under "Loss from Discontinued Operations" for the Comparable Quarter. The loss from "discontinued operations" of \$3,299,030 represents the operating losses of the telematics division for the comparable quarter. This amount includes depreciation and amortization of \$2,290,312. The loss for the discontinued operations prior to October 9, 2001 was taken as a cost in the fiscal year-end 2001. Results subsequent to October 9, 2001 are no longer a part of the Company's consolidated financial statements. In addition, in the quarter ended December 31, 2001, upon disposition of the subsidiaries operating in the telematics business the Company has recorded the reversal of the cumulative translation adjustment relative to these discontinued operations that had previously been recorded as a component of Stockholders' Equity.

Edgar Filing: CELLPOINT INC - Form 10QSB

NET LOSS AND LOSS PER SHARE. As a result of the above, net loss was (\$4,032,491) for the Current Quarter. Loss per share from continuing operations was (\$0.25) based on weighted average shares outstanding of 16,301,713, while the Comparable Quarter loss per share from continuing operations was (\$0.44) based upon a weighted average of 10,485,000 shares outstanding. The net loss for the Comparable Quarter was (\$7,919,926) including the loss from discontinued operations of (\$3,299,030).

SIX MONTHS ENDED DECEMBER 31, 2001

The results of continuing operations are reported herein for the Company's location services business. The Company's telematics division is reported as "discontinued operations".

REVENUES. In the six months ended December 31, 2001 (the "Current Period"), the Company's gross revenues from continuing operations were \$591,757, as compared to revenues from continuing operations of \$1,729,970 for the six months ended December 31, 2000 (the "Comparable Period"). All of the Company's revenues came from the European market. The decrease in revenues is considered to be a timing effect as the Company is currently engaged in several negotiations to close further contracts.

COST OF REVENUES. Costs incurred by the Company in producing revenues in the Comparable Period were mainly the costs of supplying hardware in conjunction with the sale of the previous generation of software platforms. Such costs decreased by \$320,716 to \$35,683 in the Current Period as compared to \$356,399 in the Comparable Period. The Company's role in supplying hardware in relation to its sale of software and applications is decreasing, and accordingly, the costs of producing revenue as a percentage of revenue has decreased. Research and development expenses are recorded separately.

GROSS PROFIT. For the Current Period, the Company recorded a gross profit of \$556,074 as compared to

\$1,373,571 gross profit in the Comparable Period. This decrease in gross profit is attributable to the decrease in revenues in the Current Period whilst the gross margin increased by 14.6% to 94.0% in the Current Period from 79.4% in the Comparable Period as a result of decreased need to supply hardware as part of the Company's product.

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES. The Company's selling, general and administrative expenses decreased by \$760,655 to \$2,463,746 in the Current Period from \$3,224,401 in the Comparable Period. The decrease in selling, general and administrative expenses in the Company's continuing operations was primarily due to the restructuring program. Recurring selling, general and administrative expenses are expected to decrease in future periods due to the restructuring program in place compared to the fiscal year ended June 30, 2002.

RESEARCH AND DEVELOPMENT EXPENSES. The Company's research and development expenses increased by \$590,954 to \$2,460,939 in the Current Period from \$1,869,985 in the Comparable Period. The increase in research and development expenses in the Company's continuing operations was due to the research and development of the new generation of software platforms for location-based services.

PROFESSIONAL FEES. Professional fees decreased by \$31,066 to \$651,261 in the Current Period from \$682,327 in the Comparable Period. Professional fees in the Current Period are primarily related to costs incurred in connection with regulatory compliance.

Edgar Filing: CELLPOINT INC - Form 10QSB

DEPRECIATION AND AMORTIZATION EXPENSE. Depreciation and amortization expense increased by \$139,869 to \$1,985,131 in the Current Period from \$1,845,262 in the Comparable Period. Depreciation and amortization is primarily related to purchased technology. The amortization of the positioning technology acquired in connection with the Unwire acquisition amounts to \$805,357 and \$773,758 and the amortization of the original core technology amounts to \$891,660 and \$994,163 for the six months ended December 31, 2001 and 2000, respectively.

FINANCIAL ITEMS. Financial items resulted in an expense of \$2,285,726 in the Current Period compared to a net expense of \$748,680 in the Comparable Period. Interest expense was \$2,014,576 in the Current Period, compared to \$13,490 in the Comparable Period. The increase in interest expense was attributable to the \$10,000,000 of convertible notes issued in December 2000 and the amortization of the debt discount recorded in relation to those notes and the subsequent amendments to the terms thereof resulting in non-cash expense in the Current Period of \$1,604,249. Interest expense in the Current Period consisted of the non-cash expense of \$1,604,249 on the Castle Creek debt discount, interest of \$230,327 to Castle Creek and interest of \$180,000 to M&S Trust. In the Current Period, the Company had realized foreign exchange losses aggregating \$250,044 whereas in the Comparable Period, the Company had net realized foreign exchange gain of \$6,610. These items result primarily from exchange rate fluctuations in the currencies of the United States, England and Sweden.

LOSS FROM CONTINUING OPERATIONS. Loss from continuing operations for the Current Period was (\$9,290,729) versus (\$7,339,369) in the Comparable Period. The increase in loss from continuing operations in the Current Period was a result of the increased financial costs related to the Castle Creek transaction of interest expense (\$230,247) and non-cash expense of (\$1,604,249).

INCOME/LOSS FROM DISCONTINUED OPERATIONS. On July 25, 2001, the Company publicly announced its intention to sell its telematics division. On October 9, 2001, Unwire filed for bankruptcy protection under the laws of Sweden. Under accounting principles generally accepted in the United States, the results of operations for the telematics division, are presented under "Loss from Discontinued Operations" for the Comparable Period. The loss from "discontinued operations" of (\$5,927,855) represents the operating losses of the telematics division for the comparable period. This amount includes depreciation and amortization of \$4,504,197. The loss for the discontinued operations for the Current Period was taken as a cost in the fiscal year-end 2001. In addition, in the quarter ended December 31, 2001, upon disposition of the subsidiaries operating in the telematics business the Company has recorded the reversal of the cumulative translation adjustment relative to these discontinued operations that had previously been recorded as a component of Stockholders' Equity.

NET LOSS AND LOSS PER SHARE. As a result of the above, net loss was (\$9,290,729) for the Current Period. Loss per share from continuing operations was (\$0.68) based on weighted average shares outstanding of 13,641,876, while the Comparable Period loss per share from continuing operations was (\$0.70) based upon a weighted average of 10,475,000 shares outstanding. The net loss for the Comparable Period was (\$13,267,224) including the loss from discontinued operations of (\$5,927,855).

LIQUIDITY AND CAPITAL RESOURCES

WORKING CAPITAL. At December 31, 2001, the Company had \$1,300,386 in current assets. Cash and cash equivalents amounted to \$179,729. Accounts

Edgar Filing: CELLPOINT INC - Form 10QSB

receivable was \$729,498. Current liabilities were \$14,550,071 at December 31, 2001. Included in that amount is \$2,667,869 in accrued expenses and current liabilities of which \$271,892 related to standard business payables, \$433,766 to taxes, \$140,000 to professional fees not yet billed, \$190,000 to salaries to shareholders who are also employees of the Company, accrued interest payable to Castle Creek of \$422,474, \$209,208 of deferred income not yet billed, \$212,176 remaining reserve on a previous acquisition and \$788,353 accrued for contingent costs related to liquidated subsidiaries. The Company does not expect any imminent payments in connection with these contingencies but these accruals made in prior periods will be maintained until liquidation is cleared by the trustees.

Accounts payable of \$2,805,511 includes \$518,514 invoiced from the Company's former legal counsel and is in dispute by the Company. In December 2001, the Company filed a malpractice claim against former counsel relating to work performed in connection with the Company's agreements with Castle Creek Technology Partners LLC. The claim alleges former counsel breached the duty of care owed to their client by failing to reasonably and competently represent CellPoint in the transactions associated with Castle Creek. The claim further alleges that their actions and omissions fall below the standards for reasonably competent attorneys in the preparation of documents consummating the agreements and the advice related thereto. Also included in current liabilities is \$4,576,691 of short-term debt to Castle Creek Technology Partners LLC and \$4,500,000 to M&S Trust. The Company has established payment plans for several current liabilities and payables to be paid over the next three to six months.

Long term liabilities were \$725,750 and comprised of a related party note due in April 2003 (See Note 9 to Financial Statements).

At June 30, 2001, the Company had \$4,993,093 in current assets, of which \$687,151 consisted of cash and cash equivalents. Working capital deficit at the end of the Current Quarter was (\$13,249,685), as compared to (\$2,408,779) at the end of Fiscal 2001. The decrease in working capital is attributable mainly to the reclassification of long-term debt of (\$9,076,691) to current liabilities as it is now due within 12 months of the end of the Current Quarter.

CASH FLOW FROM OPERATIONS. For the Current Period, the Company used net cash in operating activities from continuing operations of \$3,202,312 as compared to \$5,880,954 for the Comparable Period. Net cash used in operating activities from discontinued operations was \$1,094,378 in the Current Period, as compared to \$1,883,132 in the Comparable Period. The increase in net cash provided is primarily a result of decreased operating loss before depreciation and amortization and non-cash expense related to the amortization of the debt discount in connection with convertible notes. For the current fiscal year, total operating expenses are expected to continue to decrease on a quarterly basis.

On July 25, 2001, CellPoint publicly announced the planned sale of Unwire. The Company was unable to identify a purchaser for Unwire and on October 9, 2001, Unwire filed for bankruptcy protection under the laws of Sweden. The Company does not anticipate any further significant charges in relation to this bankruptcy.

CASH FLOW FROM INVESTING ACTIVITIES. For the Current Period, the Company had a net cash outflow from investing activities from continuing operations of \$259,395 versus a net cash outflow of \$85,149 in the Comparable Period whereof

\$242,864 was primarily due to ongoing research and development expenses offset by \$157,715 being proceeds from disposal of investment in affiliated

Edgar Filing: CELLPOINT INC - Form 10QSB

company. The Company does not currently have any commitments for capital expenditures during the current fiscal year, but the Company may make such expenditures if an opportunity consistent with the Company's business strategy presents itself.

CASH FLOW FROM FINANCING ACTIVITIES. For the Current Period, the Company had a net cash inflow from financing activities of \$3,116,938 versus a net cash inflow from financing activities of continuing operations of \$10,149,000 in the Comparable Period. The Company received net proceeds of approximately \$5,761,838 from sales of equity through private placements in the Current Period. Proceeds were used to repay long term debt to Castle Creek of \$3,144,900 and for working capital.

The Company will require additional capital during its fiscal year ending June 30, 2002 to carry on its business and meet its current liabilities and implement its business strategies, including cash for (i) payment of operating expenses such as salaries for employees and ongoing business costs, and (ii) further implementation of those business strategies. Such additional capital may be raised through additional public or private financing, as well as borrowings and other resources. To the extent that additional capital is raised through the sale of equity or equity-related securities, the issuance of such securities could result in dilution to the Company's stockholders. No assurance can be given, however, that the Company will have access to the capital markets in the future, or that financing will be available on acceptable terms to satisfy the Company's cash requirements to implement its business strategies. If the Company is unable to access the capital markets or obtain acceptable financing, its future results of operations and financial conditions would be materially and adversely affected. The Company may be required to raise substantial additional funds through other means. If adequate funds are not available to the Company, it may be required to curtail operations significantly or to obtain funds through entering into arrangements with collaborative partners or others that may require it to relinquish rights to certain of its technologies or product candidates that the Company would not otherwise relinquish. While the Company has begun to receive commercial revenues, there can be no assurances that its existing commercial agreements will provide adequate cash to sustain its operations. If the Company decides to expand its business faster, or to geographic areas outside of Europe during the next twelve months, it may need to raise further capital.

EFFECT OF RECENT ACCOUNTING PRONOUNCEMENTS

In June 2001, the Financial Accounting Standards Board ("FASB") finalized FASB Statements No. 141, Business Combinations (SFAS No. 141), and No. 142, Goodwill and Other Intangible Assets (SFAS No. 142). SFAS No. 141 requires the use of the purchase method of accounting and prohibits the use of the pooling-of-interests method of accounting for business combinations initiated after June 30, 2001. SFAS No. 141 also requires that the Company recognize acquired intangible assets apart from goodwill if the acquired intangible assets meet certain criteria. SFAS No. 141 applies to all business combinations initiated after June 30, 2001 and for purchase business combinations completed on or after July 1, 2001. It also requires, upon adoption of SFAS No. 142 that the Company reclassify the carrying amounts of intangible assets and goodwill based on the criteria in SFAS No. 141.

SFAS No. 142 requires, among other things, that companies no longer amortize goodwill, but instead test goodwill for impairment at least annually. In addition, SFAS No. 142 requires that the Company identify reporting units for the purposes of assessing potential future impairments of goodwill, reassess the useful lives of other existing recognized intangible assets, and cease amortization of intangible assets with an indefinite useful life. An intangible asset with an indefinite useful life should be tested for impairment in accordance with the guidance in SFAS No. 142. SFAS No. 142 is required to be

Edgar Filing: CELLPOINT INC - Form 10QSB

applied in fiscal years beginning after December 15, 2001 to all goodwill and other intangible assets recognized at that date, regardless of when those assets were initially recognized. Early adoption is permitted in the first quarter of fiscal years beginning after December 15, 2000. SFAS No. 142 requires the Company to complete a transitional goodwill impairment test six months from the date of adoption. The Company is also required to reassess the useful lives of other intangible assets within the first interim quarter after adoption of SFAS No. 142. The Company is still assessing the impact SFAS No. 142 will have on its financial position and results of operations and thus was unable to early adopt SFAS No. 142. The Company will thus adopt SFAS No. 142 on July 1, 2002.

In August 2001, the FASB issued SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets" ("SFAS No. 144"). This statement supercedes SFAS No. 121, "Accounting for the Impairment of Long-Lived

Assets and for Long-Lived Assets to Be Disposed Of" ("SFAS No. 121") and a portion of Accounting Principles Board Opinion No. 30, "Reporting Results of Operations -Reporting the Effects of Disposal of a Segment of a Business, and Extraordinary, Unusual and Infrequently Occurring Events and Transactions". SFAS No. 144 retains the fundamental provisions of SFAS No. 121 for recognition and measurement of impairment, but amends the accounting and reporting standards for segments of a business to be disposed of. SFAS No.144 is effective for fiscal years beginning after December 15, 2001, and interim periods within those fiscal years, with early application encouraged. The provisions of SFAS No. 144 generally are to be applied prospectively. The Company believes that the adoption of SFAS No. 144 will not have a material impact on the Company's financial position or results of operations.

DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this Report contain "forward looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These are statements that do not relate strictly to historical or current facts. Although the Company believes that its plans, intentions and expectations reflected in such forward looking statements are reasonable, it can give no assurance that such plans, intentions or expectations will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties. The Company's actual actions or results may differ materially from those discussed in the forward-looking statements. These risk factors are set forth below. All forward looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth below:

- o Our limited operating history makes evaluation of our business and prospects difficult;
- o Our business and prospects must be considered in light of the risks, uncertainties, expenses and difficulties frequently encountered by companies in their early stages of development, particularly companies in new and rapidly evolving markets, such as the market for location services;
- o We have been sued by Castle Creek Technology Partners, LLC, which has provided us financing, to have our debt of in excess of \$6 million declared due and payable, for a default payment of \$2 million and other damages and relief (See "Legal Proceedings"), based on an alleged failure on our part to register an increased number of shares for Castle Creek due to the operation of antidilution provisions in a warrant we issued to Castle Creek in July 2001. On December 19, 2001, we entered into a Stipulation and

Edgar Filing: CELLPOINT INC - Form 10QSB

Order with Castle Creek providing that Castle Creek agreed to stay prosecution of this case until February 28, 2002, provided that we make required prepayments on our Notes to Castle Creek of \$200,000 by January 31, 2002, which payment was timely made, and an additional \$550,000 by February 28, 2002 and provided, further, that we do not breach our agreements and instruments with Castle Creek subsequent to the date of the Stipulation and Order. If we are in compliance with the provisions of the Stipulation and Order at February 28, 2002, then Castle Creek will dismiss the case with prejudice. We are also required to make prepayments of the Notes in an amount equal to 25% of the gross proceeds of each financing we close; provided, that the maximum aggregate amount of prepayments that we are required to make under the Stipulation and Order prior to October 1, 2002 (the due date of the Notes) is \$3,000,000.

- o Our sales cycles are long and our revenue is unpredictable;
- o Our ability to secure additional financing on acceptable terms to carry on our business and meet current liabilities and ongoing expenses as and when necessary;
- o Our ability to improve our technology to keep up with customer demand for new services;
- o The development cycle for new products may be significantly longer than expected, resulting in higher than anticipated development costs;
- o The ability of our systems and operations to connect and manage a substantially larger number of customers while maintaining adequate performance, which could place a strain on managerial and operational resources;
- o Our ability to expand customer service, billing and other related support systems;
- o Our ability to retain the services of our key management and to attract new members of our management team;
- o Our ability to effect and retain appropriate patent, copyright and trademark protection of our products;
- o Despite the implementation of security measures, our computer networks and web sites may be vulnerable to unauthorized access, computer viruses and other disruptive problems, and any such occurrence could result in the expenditure of additional resources necessary to protect our assets;
- o Increased competition in the field of location services;
- o Our ability to make required payments on and to retire the outstanding convertible notes held by Castle Creek Technology Partners, LLC, pursuant to the terms of the Note Purchase, Modification and Forebearance Agreement, dated as of July 25, 2001, as amended as of September 26, 2001, and by the Stipulation and Order with Castle Creek.
- o Our ability to continue to meet the listing requirements of the Nasdaq National Market. On November 21, 2001, The Nasdaq Stock Market notified us of its staff determination that we did not comply

Edgar Filing: CELLPOINT INC - Form 10QSB

with the minimum net tangible assets or the stockholders equity listing standards and requested that we submit a definitive plan for compliance with these standards. We submitted our plan in response to this notice on December 17, 2001. Due to the change in our financial statements for the quarter ended September 30, 2001, set forth herein, we have been advised by Nasdaq that this proceeding is moot.

ITEM 8. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

PART II

ITEM 1. LEGAL PROCEEDINGS

PENDING LEGAL PROCEEDINGS

As described elsewhere in this report, the Company is party to a Securities Purchase Agreement, dated December 6, 2000, with Castle Creek Technology Partners LLP ("Castle Creek"), pursuant to which it issued \$10,000,000 principal amount of its convertible notes (the "Notes") to Castle Creek, a Stock Purchase Warrant, dated December 6, 2000, entitling Castle Creek to purchase additional shares of the Company's common stock, and a related Registration Rights Agreement, dated December 6, 2000, providing for registration with the Securities and Exchange Commission ("SEC") of the shares of common stock owned by Castle Creek and issuable pursuant to said convertible notes and stock purchase warrant for resale. On July 25, 2001, the Company and Castle Creek Technology Partners LLC ("Castle Creek") entered into a Note Purchase, Modification and Forebearance Agreement (the "July Agreement"), pursuant to which the Company agreed to purchase over 90 days for 86% of face value of the then remaining \$9.25 million principal amount in convertible notes held by Castle Creek. The Company agreed to pay \$3.0 million to Castle Creek by September 24, 2001 and \$4.955 million by October 23, 2001 (of which \$1.0 million was paid as a non-refundable deposit on July 25, 2001), plus all accrued and unpaid interest from the original issuance date through October 23, 2001 or, if earlier, the date of the purchase. As part of the transaction, the Company issued to Castle Creek five-year warrants to purchase 500,000 shares of Common Stock, exercisable, after one year, at an initial exercise price of \$3.14 per share (subject to specified anti-dilution adjustment as set forth in the terms of such warrants). The shares issuable upon exercise of such warrant were required to be registered with the Securities and Exchange Commission.

In addition, the Company granted to Castle Creek a security interest in its assets (including the assets of its

subsidiaries), including its intellectual property. The fixed conversion price of the notes was changed to \$4.00 with no floating conversion price if the notes were purchased on a timely basis and the Company was in compliance with all its other obligations to Castle Creek in all material respects. The Company also agreed to certain limitations on the terms of future debt and equity financings, which limitations would not apply to a financing that provided the proceeds for the final purchase of the Notes. The Company granted Castle Creek a full release of all claims and agreed not to disparage Castle Creek; Castle Creek has agreed not to disparage the Company.

On September 26, 2001, CellPoint and Castle Creek entered into an amendment of the July Agreement to repurchase the convertible notes held by

Edgar Filing: CELLPOINT INC - Form 10QSB

Castle Creek and related matters. Pursuant to the amendment, the Company paid \$2.25 million to Castle Creek on September 26, 2001 for principal and accrued interest. The remaining outstanding convertible notes are subject to a fixed conversion price of \$4.00, and are scheduled to be, repurchased on October 1, 2002 for approximately \$6.1 million plus accrued interest (and, in the event of a material breach by the Company, such prices will be then subject to specified adjustments by a reset of the fixed conversion price to the lower of (a) the average closing price during the ten-day period beginning five days prior to the date of such non compliance event, or (b) the lowest price at which the Company's Common Stock or Common Stock equivalents are sold after September 25, 2001, and by the payment of an additional repurchase amount of \$2,000,000). The outstanding notes are prepayable in part or in whole at any time, without penalty.

The Company was served with a complaint on November 15, 2001, for a suit by Castle Creek to have its debt of in excess of \$6 million declared due and payable, for a default payment of \$2 million and other damages and relief, and on December 13, 2001, Castle Creek filed an amended complaint. The principal issue in dispute in the litigation is a declaratory judgment sought by Castle Creek as to the antidilution adjustment applicable to the number of shares that Castle Creek is entitled to purchase under the warrant to purchase 500,000 shares of common stock issued in the July 25, 2001 restructuring with Castle Creek. On December 19, 2001, the Company entered into a Stipulation and Order with Castle Creek providing that Castle Creek agreed to stay prosecution of this case until February 28, 2002, provided that the Company makes required prepayments on its Notes to Castle Creek of \$200,000 by January 31, 2002, which payment was timely made, and an additional \$550,000 by February 28, 2002 and provided, further, that the Company does not breach its agreements and instruments with Castle Creek subsequent to the date of the Stipulation and Order. If the Company is in compliance with the provisions of the Stipulation and Order at February 28, 2002, then Castle Creek will dismiss the case with prejudice. The Company is also required to make prepayments of the Notes in an amount equal to 25% of the gross proceeds of each financing it closes; provided, that the maximum aggregate amount of prepayments that the Company is required to make under the Stipulation and Order prior to October 1, 2002 (the due date of the Notes) is \$3,000,000. The Company has also registered in its Registration Statement that was declared effective by the Securities and Exchange Commission on January 8, 2002, the 1,500,000 shares issuable to Castle Creek by reason of the Stipulation and Order for the July 2001 warrant.

CLAIM FILED AGAINST FORMER COUNSEL

In December 2001, the Company filed a \$100 million malpractice claim against its former legal counsel, relating to work performed by that firm in negotiation of agreements with Castle Creek. This firm represented the Company in contract negotiations and documented the details of the private placement in which Castle Creek purchased the Notes. This firm also worked on subsequent agreements and modifications with Castle Creek in July and September, 2001. The claim alleges this firm breached the duty of care owed to its client by failing to reasonably and competently represent the Company in the transactions associated with Castle Creek. The claim further alleges that their actions and omissions fall below the standards for reasonably competent attorneys in the preparation of documents consummating the agreements and the advice related thereto. The Company in this suit alleges that it has suffered damages as a direct and proximate result of the malpractice of these attorneys in an amount to be determined at trial, but no less than \$100 million, plus interest, attorneys' fees, costs and punitive damages.

AROSMAIZELS AB ARBITRATION

The Company had received a claim by ArosMaizels AB for 5,700,000 Swedish Kronor (approximately \$550,000) for financial services rendered to the

Edgar Filing: CELLPOINT INC - Form 10QSB

Company in connection with the Unwire transaction and potential financings. This claim was submitted for arbitration, as a result of which, the Company is required to pay 4,500,000 Swedish Kronor (approximately \$425,000) plus interest at 8% from May 3, 2001. The Company previously recorded a reserve for this

claim and intends to pay it in full.

ITEM 2. CHANGES IN SECURITIES

- (a) None.
- (b) None.
- (c) Recent Sales of Securities.

In late September and early October, 2001, the Company closed three private Placements of its common stock and warrants to purchase common stock: the first placement was for \$3.25 million, pursuant to which the Company issued 3,250,000 shares of Common Stock plus 1,625,000 warrants to purchase shares of Common Stock at an exercise price of \$2.25 per share, exercisable for two years. The units were sold to accredited investors pursuant to Regulation 506 under the Securities Act of 1933, as amended (the "Securities Act"). The proceeds from the sale of these units were used to repurchase a portion of the convertible notes held by Castle Creek. The second placement was an offering pursuant to Regulation S under the Securities Act, in which non-U.S. Persons (as such term is defined in Regulation S), purchased 1,568,144 shares of Common Stock and 784,071 warrants to purchase shares of Common Stock, exercisable at \$2.36 per share for two years. The proceeds from the Regulation S offering aggregated \$2,071,130, and will be used for working capital. The third placement was for shares of Common Stock and warrants to purchase Common Stock for \$1,300,000. Such offering was made to accredited investors pursuant to Regulation 506 under the Securities Act. In connection with such offering, the Company issued 1,238,096 shares of Common Stock, and 619,048 warrants to purchase shares of Common Stock, half of which are exercisable at \$3.50 per share for twelve months and the other half of which are exercisable at \$5.00 per share for twenty-four months.

- (d) None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

On December 12, 2001, the Company held its annual meeting of stockholders. At the meeting, the stockholders voted on (i) the proposal to elect as directors the persons who have been nominated by the current Board of Directors of the Company, (ii) the proposal to approve the amendment to the Company's Articles of Incorporation to increase the authorized common stock of the Company from 22,000,000 shares of common stock, par value \$.001 per share, to 50,000,000 shares of common stock, par value \$.001 per share, (iii) the proposal to approve the amendment to the Company's Articles of Incorporation to increase the authorized preferred stock of the Company from 3,000,000 shares of non-voting preferred stock, par value \$.001 per share, to 10,000,000 shares of

Edgar Filing: CELLPOINT INC - Form 10QSB

preferred stock, par value \$.001 per share, having such rights and preferences, including voting rights, as the Board of Directors of the Company may determine, (iii) the adoption of an amendment to the Company's Stock Warrant Plan, and (iv) the proposal to ratify the retention of BDO Seidman, LLP as the independent auditors of the Company.

(i) The proposal to elect persons to serve as directors of the Company; Stephen Childs, Lynn Duplessis, Peter Henricsson, Lars Person, Bengt Nordstrom and Jan Rynning received an average of 10,261,193 votes in favor of each nominee, an average of 103,777 votes against and 0 abstentions and broker non-votes, representing an average vote of 99% of the votes cast in favor of the election of directors.

Individual votes:

	For	Withheld	% of votes cast
Stephen Childs	10 261 076	106 095	99%
Lynn Duplessis	10 278 581	88 590	99%
Peter Henricsson	10 257 476	109 695	99%

Bengt Nordstrom	10 261 076	106 095	99%
Lars Persson	10 261 076	106 095	99%
Jan Rynning	10 261 076	106 095	99%

(ii) the proposal to approve an amendment to the Company's Articles of Incorporation to increase the authorized common stock of the Company from 22,000,000 shares of common stock to 50,000,000 shares of common stock was adopted, having received 10,340,165 votes in favor, 26,548 votes against and 458 abstentions and broker non-votes, representing a vote of 63% of the total shares outstanding and 99.7% of the votes cast in favor of the proposal;

(iii) the proposal to approve an amendment to the Company's Articles of Incorporation to increase the authorized preferred stock of the Company from 3,000,000 shares of preferred stock to 10,000,000 shares of preferred stock, par value \$.001 per share, having such rights and preferences, including voting rights, as the Board of Directors of the Company may determine was not adopted, having received 6,141,864 votes in favor, 35,428 votes against and 4,189,879 abstentions and broker non-votes, representing a vote of 37% of the total shares outstanding in favor of the proposal, less than the minimum of 50% of the total shares outstanding required for adoption ;

(iv) the proposal to approve an amendment to the Company's 1998 Stock Warrant Plan was adopted, having received 10,336,225 votes in favor, 29,948 votes against and 998 abstentions and broker non-votes, representing a vote of 63% of the total shares outstanding and 99.8% of the votes cast in favor of the proposal; and

(v) the retention of BDO Seidman LLP for audit responsibility as the Company's independent auditors was ratified, having received 10,354,048 votes in favor, 12,673 votes against and 450 abstentions and broker non-votes, representing a vote of 63% of the total shares outstanding and 99.9% of the votes cast in favor.

Edgar Filing: CELLPOINT INC - Form 10QSB

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS, LIST AND REPORTS ON FORM 8-K

- (a) Exhibits
- (b) Reports on Form 8-K

Current Reports on Form 8-K were filed on July 31, 2001, October 5, 2001, and on December 21, 2001.

CELLPOINT INC. AND SUBSIDIARIES

CONTENTS

Consolidated balance sheets as of December 31, 2001 (Unaudited) and June 30, 2001 (Audited).....

Consolidated statements of operations for the six months ended December 31, 2001 and 2000.....

Consolidated statements of comprehensive income/(loss) for the six months period ended December 31, 2001 and 2000.....

Consolidated statements of cash flows for the six months period ended December 31, 2001 and 2000.....

Notes to consolidated financial statements.....

CELLPOINT INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(AMOUNTS IN USD)

NOTE

Edgar Filing: CELLPOINT INC - Form 10QSB

ASSETS	
CURRENT ASSETS	
Cash and cash equivalents	
Accounts receivable	
Unbilled receivables	
Prepaid expenses and other current assets	
Other receivables	
Current assets of discontinued operations	2
TOTAL CURRENT ASSETS	
LONG-TERM ASSETS	
Restricted cash	7
Acquired technology, net of accumulated amortization of \$6,941,953 and \$5,411,604, respectively	
Other intangible assets, net of accumulated amortization of \$1,541,005 and \$1,311,830, respectively	
Property and equipment, net of accumulated depreciation of \$1,045,102 and \$480,345, respectively	
Non-current assets of discontinued operations	2
TOTAL LONG-TERM ASSETS	
TOTAL ASSETS	
LIABILITIES AND STOCKHOLDERS' EQUITY	
CURRENT LIABILITIES	
Accrued expenses and other current liabilities	10
Accounts payable	
Current maturities of long-term debt (net of debt discount of \$1,528,409 and nil, respectively)	3
Current liabilities of discontinued operations	
TOTAL CURRENT LIABILITIES	
DUE TO RELATED PARTY	9
LONG-TERM DEBT (net of debt discount of nil and \$1,914,490)	3
TOTAL LIABILITIES	
MINORITY INTEREST	
COMMITMENTS AND CONTINGENCIES	3
STOCKHOLDERS' EQUITY	
Preferred shares (\$0.001 par value; authorized 3,000,000 shares, nil issued and outstanding)	
Common shares (\$0.001 par value; authorized 50,000,000 shares, 16,355,543 shares and 10,824,503 shares issued and outstanding, respectively)	
Common shares to be issued	4
Additional paid in capital	
Cumulative foreign currency translation adjustment	
Stock subscription receivable	4
Accumulated deficit	
TOTAL STOCKHOLDERS' EQUITY	
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	

Edgar Filing: CELLPOINT INC - Form 10QSB

See accompanying notes to the consolidated financial statements

CELLPOINT INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (AMOUNTS IN USD)

	NOTE	THREE MONTHS ENDED	
		DECEMBER 31, 2001 (unaudited)	DECEMBER 31, 2000 (unaudited)
Revenues		\$ 176,552	\$ 804,417
Cost of revenues		(14,637)	(127,566)
		-----	-----
Gross profit		161,915	676,851
Selling, general and administrative expense ..	5	(599,929)	(1,869,623)
Research and development expense		(1,388,832)	(1,090,685)
Professional fees		(485,585)	(460,829)
Depreciation and amortization		(974,912)	(935,288)
		-----	-----
TOTAL OPERATING EXPENSES		(3,449,258)	(4,356,425)
		-----	-----
LOSS FROM OPERATIONS		(3,287,343)	(3,679,574)
Loss on sale on investment		--	(342,285)
Financial items, net	8	(745,148)	(599,037)
		-----	-----
LOSS FROM CONTINUING OPERATIONS		(4,032,491)	(4,620,896)
		-----	-----
INCOME/(LOSS) FROM DISCONTINUED OPERATIONS ...	2	1,525,670	(3,299,030)
		-----	-----
NET LOSS		\$ (2,506,821)	\$ (7,919,926)
		=====	=====
Weighted average number of shares outstanding, basic and diluted		16,301,713	10,485,000
		-----	-----
Net loss per common share basic and diluted:			
Continuing operations		\$ (0.25)	\$ (0.44)
Discontinued operations		\$ 0.09	\$ (0.31)
Net loss per share		\$ (0.16)	\$ (0.76)

See accompanying notes to the consolidated financial statements

CELLPOINT INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (AMOUNTS IN USD)

Edgar Filing: CELLPOINT INC - Form 10QSB

	THREE MONTHS ENDED		SIX
	DECEMBER 31, 2001 (unaudited)	DECEMBER 31, 2000 (unaudited)	DECEMBER 31, 2001 (unaudited)
Net loss	\$ (2,506,821)	\$ (7,919,926)	\$ (7,765,059)
Other comprehensive income (loss), cumulative foreign exchange adjustments	(1,433,215)	17,205	(1,266,109)
Comprehensive loss for the period	\$ (3,940,036)	\$ (7,902,721)	\$ (9,031,168)

See accompanying notes to the consolidated financial statements

CELLPOINT INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(AMOUNTS IN USD)

NOTE 6	SIX MONTHS ENDED DECEMBER 31, 2001 (unaudited)	SIX M END DECEM 20 (unau
CASH FLOWS FROM OPERATING ACTIVITIES		
Net loss	\$ (7,765,059)	\$ (13,2
ADJUSTMENTS TO RECONCILE NET LOSS TO NET CASH PROVIDED BY OPERATING ACTIVITIES:		
(Income)/Loss from discontinued operations	(1,525,670)	5,9
Depreciation and amortization	1,985,131	1,8
Provision for allowance on accounts receivables	--	(
Non-cash financing costs	1,604,249	1
Reversal of cumulative translation adjustment related to liquidated subsidiaries	(127,506)	
Loss on disposal of investment in affiliated company	--	3
CHANGES IN OPERATING ASSETS AND LIABILITIES:		
Increase in restricted cash	(203,187)	
Decrease/(increase) in accounts receivable	637,143	(4
Decrease/(increase) in unbilled receivables	792,443	
Decrease/(increase) in prepaid expenses	225,541	
Decrease/(increase) in other receivables	169,010	(4
Increase/(decrease) in accrued expenses and other current liabilities	330,803	1
Increase/(decrease) in accounts payable	674,790	
Decrease in due to affiliate	--	(
NET CASH USED IN OPERATING ACTIVITIES FROM CONTINUING OPERATIONS:	(3,202,312)	(5,8
NET CASH USED IN OPERATING ACTIVITIES FROM DISCONTINUED OPERATIONS:	(1,094,378)	(1,8
NET CASH USED IN OPERATING ACTIVITIES:	(4,296,690)	(7,7
CASH FLOWS FROM INVESTING ACTIVITIES		
Capital expenditures	(259,395)	(2
Proceeds from disposal of investment in affiliated company	--	1

Edgar Filing: CELLPOINT INC - Form 10QSB

NET CASH USED IN INVESTING ACTIVITIES FROM CONTINUED OPERATIONS:	(259,395)	
NET CASH USED IN INVESTING ACTIVITIES FROM DISCONTINUED OPERATIONS:	(3,429)	
<hr/>		
NET CASH USED IN INVESTING ACTIVITIES:	(262,824)	(1,000,000)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Repayment of note payable	(3,144,900)	
Proceeds from notes payable	--	10,000,000
Net proceeds from private placements	5,339,321	
Proceeds from issuance of shares	--	1,000,000
Due to related party	725,750	
Advances of bank loans	500,000	
<hr/>		
NET CASH PROVIDED BY FINANCING ACTIVITIES FROM CONTINUING OPERATIONS:	3,420,171	10,100,000
<hr/>		
Effects of exchange rate changes on cash	634,113	
Effects of exchange rate changes on cash from discontinued operations ..	(2,192)	
<hr/>		
Increase/(decrease) in cash and cash equivalents	(507,422)	2,100,000
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	687,151	6,600,000
<hr/>		
CASH AND CASH EQUIVALENTS AT END OF PERIOD	\$ 179,729	\$ 8,700,000
<hr/>		

See accompanying notes to the consolidated financial statements

CELLPOINT INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (AMOUNTS IN USD)

1 BASIS OF PRESENTATION

NATURE OF REPORT. The consolidated balance sheet at the end of the preceding fiscal year has been derived from the audited consolidated balance sheet contained in the Company's Annual Report on Form 10-KSB, on file with the Securities and Exchange Commission, and is presented for comparative purposes. All other financial statements are unaudited. The unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Item 310 of Regulation S-B. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. The financial information included in the quarterly report should be read in conjunction with the Company's audited financial statements and related notes thereto for the fiscal year ended June 30, 2001. In the opinion of management, all adjustments necessary to present fairly the financial position, results of operations and changes in cash flows, for all periods presented, have been made. The results of operations for interim periods are not necessarily indicative of the operating results for the full year.

GOING CONCERN. The consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has recurring losses from operations and operating cash constraints that raise substantial doubt about the Company's ability to continue as a going concern.

The consolidated financial statements do not include adjustments relating to the

Edgar Filing: CELLPOINT INC - Form 10QSB

recoverability and classification of recorded asset amounts, or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company's ability to continue as a going concern is dependent on its ability to generate sufficient cash flow to meet its obligations on a timely basis and to raise additional financing to pay current liabilities. There can be no assurances that the Company will be successful in these efforts.

ESTIMATES AND UNCERTAINTIES. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

RECLASSIFICATIONS. Certain amounts relating to the six-months ended December 31, 2000 have been reclassified to conform to the current year presentation.

EFFECT OF RECENTLY ISSUED ACCOUNTING STANDARDS. In June 2001, the Financial Accounting Standards Board ("FASB") finalized FASB Statements No. 141, "Business Combinations" (SFAS No. 141), and No. 142, "Goodwill and Other Intangible Assets" (SFAS No. 142). SFAS No. 141 requires the use of the purchase method of accounting and prohibits the use of the pooling-of-interests method of accounting for business combinations initiated after June 30, 2001. SFAS No. 141 also requires that the Company recognize acquired intangible assets apart from goodwill if the acquired intangible assets meet certain criteria. SFAS No. 141 applies to all business combinations initiated after June 30, 2001 and for purchase business combinations completed on or after July 1, 2001. It also requires, upon adoption of SFAS No. 142 that the Company reclassify the carrying amounts of intangible assets and goodwill based on the criteria in SFAS No. 141.

SFAS No. 142 requires, among other things, that companies no longer amortize goodwill, but instead test goodwill for impairment at least annually. In addition, SFAS No. 142 requires that the Company identify reporting units for the purposes of assessing potential future impairments of goodwill, reassess the useful lives of other existing recognized intangible assets, and cease amortization of intangible assets with an indefinite useful life. An intangible asset with an indefinite useful life should be tested for impairment in accordance with the guidance in SFAS No. 142. SFAS No. 142 is required to be applied in fiscal years beginning after December 15, 2001 to all goodwill and other intangible

assets recognized at that date, regardless of when those assets were initially recognized. Early adoption is permitted in the first quarter of fiscal years beginning after December 15, 2000. SFAS No. 142 requires the Company to complete a transitional goodwill impairment test six months from the date of adoption. The Company is also required to reassess the useful lives of other intangible assets within the first interim quarter after adoption of SFAS No. 142.

The Company has not completed its assessment of the impact SFAS No. 142 will have on its financial position and results of operations and thus was unable to early adopt SFAS No. 142. The Company will thus adopt SFAS No. 142 on July 1, 2002.

In August 2001, the FASB issued SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets". This statement supercedes SFAS No. 121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of" ("SFAS No. 121") and a portion of Accounting

Edgar Filing: CELLPOINT INC - Form 10QSB

Principles Board Opinion No. 30, "Reporting Results of Operations - Reporting the Effects of Disposal of a Segment of a Business, and Extraordinary, Unusual and Infrequently Occurring Events and Transactions". SFAS No. 144 retains the fundamental provisions of SFAS No. 121 for recognition and measurement of impairment, but amends the accounting and reporting standards for segments of a business to be disposed of. SFAS No.144 is effective for fiscal years beginning after December 15, 2001, and interim periods within those fiscal years, with early application encouraged. The provisions of SFAS No. 144 generally are to be applied prospectively. The Company believes that the adoption of SFAS No. 144 will not have a material impact on the Company's financial position or results of operations.

2 DISCONTINUED OPERATIONS

On May 19, 2001, the Company approved the disposal of the telematics business segment of the Company and committed to a plan to dispose of the business. In October and November 2001, the two subsidiaries that contained the telematics business segment filed for protection under the bankruptcy court. As a result of the filings the Company ceased all funding of the telematics business segment and relinquished to the respective bankruptcy courts control over the operations and decision making capabilities of the former subsidiaries (See also Note 5). Accordingly, the telematics business segment was presented as a discontinued operation in the balance sheet as of June 30, 2001. The statements of operations and cash flows for the six months ended December 31, 2000, have been restated to conform with this presentation. At June 30, 2001, the Company had accrued approximately \$1,100,000 for additional losses expected from the discontinued operation through the expected date of disposition. For the six months ended December 31, 2001 the Company has incurred losses of approximately \$1,085,000 against the accrual. The Company does not anticipate any further significant losses related to this segment. From the time the business ceased to be under the control of the Company, its financial statements have ceased to be included in the Company's consolidated financial statements. Losses through the date at which control was relinquished are included in the Company's Accumulated Deficit. In addition, in the quarter ended December 31, 2001, upon disposition of the related subsidiaries the Company has recorded the reversal of the cumulative translation adjustment relative to these discontinued operations that had previously been recorded as a component of Stockholders' Equity.

The continuing operations of the Company now constitute the only reportable business segment.

The components of assets (liabilities) of discontinued operations included in the Company's Consolidated Balance Sheet at June 30, 2001 are as follows:

	DECEMBER 31, 2001	JUNE 30, 2001
Current assets:		
Cash and cash equivalents	-	\$ --
Accounts receivable	-	262,504
Prepaid expenses and other current assets	-	--
Other receivables	-	482,423
Inventory	-	429,432
Other current assets	-	186,789
Non-current assets:		

Edgar Filing: CELLPOINT INC - Form 10QSB

Other long-term assets	-	521,401
Current liabilities:		
Accounts payable, accrued expenses and other current liabilities	-	(2,982,549)
	-----	-----
Net liabilities of discontinued operations	-	\$(1,100,000)
	-----	-----

3 LONG TERM DEBT

	DECEMBER 31, 2001	JUNE 30, 2001
M&S Trust	\$4,500,000	\$ 4,000,000
Castle Creek (a)	4,576,691	7,785,510
	-----	-----
	\$9,076,691	\$11,785,510
	-----	-----

(a) Castle Creek.

On December 6, 2000, the Company entered into an agreement whereby it issued to Castle Creek Technology Partners LLC ("Castle Creek") convertible notes in the aggregate principal amount of \$10,000,000, which were originally due and payable on September 30, 2002. Interest on the debt is 6% per annum, compounded semi-annually and payable semi-annually on each June 30 and December 31. Prior to June 5, 2001, the notes were convertible, in whole or in part, at a fixed conversion price of \$25 per share at the option of the holder of the debt and could be converted in exchange for all or part of the outstanding debt plus the accrued interest at the conversion date. Subsequent to June 5, 2001, the notes were convertible at the lower of \$25 or 90% of the average of the five lowest volume weighted average prices during the period of twenty consecutive trading days ending on the trading day immediately prior to the date of determination. The conversion of the notes contained certain limitations as set forth in the agreement. The Company has reserved 2,000,000 shares for the purpose of possible future conversions.

In connection with the convertible notes, the Company issued a warrant that was immediately exercisable and which expires on December 5, 2005. The warrant grants Castle Creek the right to purchase 210,526 shares of the Company's common stock at an exercise price per share of \$11.40.

On July 25, 2001, the Company entered into a note purchase, modification and forbearance agreement with Castle Creek concerning the above mentioned notes. Under the agreement, the outstanding notes were to be repurchased by the Company. The Company agreed to buy back the outstanding principal of the notes over 90 days for 86% of the remaining principal, plus accrued interest, and issued a warrant with 500,000 shares issuable upon exercise of the warrant at an exercise price of \$3.14 per share and exercisable

Edgar Filing: CELLPOINT INC - Form 10QSB

after one year for a period of four years (subject to specified anti-dilution adjustments). In addition, the Company granted to Castle Creek a security interest in its assets (including the assets of its subsidiaries), including its intellectual property. Castle Creek agreed not to trade in the Company's stock effective July 25, 2001 until the note repurchase is completed, in consideration for which Castle Creek was paid \$1,000,000 as a non-refundable deposit against the final note purchase payment. The fixed conversion price of the Notes was changed to \$4.00 with no floating conversion price if the notes are purchased on a timely basis and the Company complies with all its other obligations to Castle Creek in all material respects. The Company also agreed to certain limitations on the terms of future debt and equity financings, which limitations would not apply to a financing that provided the proceeds for the final purchase of the Notes.

On September 26, 2001, the Company and Castle Creek entered into an amendment of the July 25, 2001 agreement, wherein the outstanding convertible notes were to be repurchased at 100% of the remaining principal and subject to a fixed conversion price of \$4.00. The Company paid \$2,250,000 to Castle Creek on September 26, 2001 for principal and accrued interest and was scheduled to make a final payment on October 1, 2002 for \$6,105,100 plus accrued interest (subject to specified adjustments upon a material breach by the Company). The outstanding notes are prepayable in part or in whole at any time without penalty. However, if the Company is in non-compliance of the limitations on the terms of future debt and equity financing, there will be a \$2,000,000 penalty and the notes will become convertible at the lower of 1) the average closing price during the ten day period beginning five days prior to the date of

the non-compliance event or (2) the lowest price of common stock or common stock equivalents sold from September 25, 2001 to the non-compliance event. The July agreement, except as modified by the amendment, remains in effect, except as further modified by the Stipulation and Order discussed below.

On November 15, 2001, the Company was served with a suit by Castle Creek, and on December 13, 2001, Castle Creek filed an amended complaint, to have its debt of in excess of \$6,100,000 principal plus interest declared due and payable, for a default payment of \$2,000,000 and other damages and relief. The principal issue in dispute in the litigation was the antidilution adjustment applicable to the number of shares that Castle Creek is entitled to purchase under the warrant issued in the July 25, 2001 restructuring with Castle Creek to purchase 500,000 shares of common stock.

On December 19, 2001, the Company entered into a Stipulation and Order with Castle Creek providing that Castle Creek agreed to stay prosecution of this case until February 28, 2002, provided that the Company makes required prepayments on its Notes to Castle Creek of \$200,000 by January 31, 2002, and an additional \$550,000 by February 28, 2002 and provided, further, that the Company does not breach its agreements and instruments with Castle Creek subsequent to the date of the Stipulation and Order. In addition, the Stipulation and Order provided a change in exercise price of the December 2000 warrant from \$11.40 to \$7.75 and the July 2001 warrant that carried anti-dilution provisions was amended to give Castle Creek the right to purchase 1,500,000 shares at a new exercise price of \$1.20 per share. 50% of the 1,500,000 shares are exercisable immediately and the balance are exercisable beginning July 25, 2002 with all shares expiring on July 25, 2006. The anti-dilution feature was further modified such that the number of shares that Castle Creek is entitled to purchase under the July 2001 Warrant was fixed at 1,500,000 (subject to adjustments for stock splits, stock dividends and combinations of shares, and like events, but not subject to adjustment due to a decrease in the exercise price of the Warrant). Procedures clarifying the manner of calculating the adjustments to the exercise price of the July 2001 Warrant were incorporated in the Stipulation and Order.

Edgar Filing: CELLPOINT INC - Form 10QSB

If the Company is in compliance with the provisions of the Stipulation and Order at February 28, 2002, then Castle Creek will dismiss the case with prejudice. The Company is also required to make prepayments of the Notes in an amount equal to 25% of the gross proceeds of each financing the Company closes; provided, that the maximum aggregate amount of prepayments that the Company is required to make under the Stipulation and Order prior to October 1, 2002 (the due date of the Notes) is \$3,000,000.

As of December 31, 2001, Castle Creek had converted \$750,000 of the notes into 270,592 shares.

Following each of the debt modifications, the Company applied the rules of Emerging Issues Task Force ("EITF") 96-19: "Debtor's Accounting for a Modification or Exchange of Debt Instruments." Based on the provisions of EITF 96-19 it was determined that there was not a substantial change from the original debt agreement and as such, the modified debt continues to be presented at fair value using the new effective interest rate. Legal fees associated with the modifications were expensed in the periods in which they were incurred.

Due to the beneficial conversion features associated with the financing, the Company applied EITF 00-27: Application of EITF No. 98-5 "Accounting for Convertible Securities with Beneficial Conversion Features or Contingently Adjustable Conversion Ratios", to the convertible instruments. In accordance with EITF 00-27 the value of the beneficial conversion feature was recorded as a reduction to the carrying amount of the convertible debt and an addition to paid-in-capital. The fair value of the warrants granted in connection with the financing and the amendments thereto was calculated using the Black Scholes pricing model and recorded as a further reduction to the carrying amount and an addition to paid-in-capital.

As a result of the private placements at the end of the first quarter the anti-dilution provision attached to the warrants issued on July 25, 2001 became effective. As such, the Company recalculated and adjusted the exercise price and therefore adjusted the number of shares issuable upon exercise of the warrants. This resulted in an adjusted exercise price of \$1.42 and additional shares of 608,235 issuable upon exercise of the warrants. The adjustment to the exercise price of the warrants increased the value of the warrants recorded as debt discount by \$263,553. The terms of this warrant were further modified by the Stipulation and Order discussed above. As a result of the changes provided by the Stipulation and Order, a further discount of \$248,574 was recorded.

The Company has therefore recorded a total debt discount of approximately \$4,026,000 and is amortizing the discount over the term of the debt. Amortization is accelerated when necessary for conversions and repayments of the debt principal. Amortization for the three and six month periods ended December 31, 2001 and 2000 was approximately \$483,000, \$128,000, \$1,604,000 and \$128,000, respectively, and is recorded as a component of financial

items.

See also Note 9.

4 EQUITY FINANCING

On September 25, 2001, the Company closed a private placement pursuant to which it issued 3,250,000 shares of Common Stock for proceeds of \$3,250,000. In addition, the Company issued warrants to purchase 1,625,000 shares of Common Stock, exercisable at \$2.25 per share for two years. The Company used part of the proceeds from this offering to make the initial required payment to Castle Creek for the repurchase of a portion of the convertible notes held by Castle

Edgar Filing: CELLPOINT INC - Form 10QSB

Creek.

On September 25, 2001, the Company closed a placement under Regulation S for an aggregate of \$2,071,130, pursuant to which the Company issued an aggregate of 1,568,144 shares and 784,071 warrants to purchase shares of the Company's Common Stock, exercisable at \$2.36 per share for two years.

As a result of the private placements, the Company has received proceeds totaling approximately \$5,762,000 by December 31, 2001. Commitments totaling approximately \$859,000 have been reported as Stock subscriptions receivable in Stockholders' equity. Shares of the Company's Common Stock in relation to the Stock subscription receivable have not been issued and thus they have been reflected in Stockholders' equity as Common Shares to be issued at December 31, 2001.

On October 5, 2001, the Company completed the initial closing of a private placement of Common Stock and warrants pursuant to which it issued an aggregate of 1,238,096 shares of Common Stock for proceeds of \$1,300,000. In addition, the Company issued warrants to purchase 619,048 shares of Common Stock, half of which are exercisable at \$3.50 per share for twelve months following the closing, and the other half of which are exercisable at \$5.00 per share for twenty-four months following the closing.

5 LIQUIDATION OF SUBSIDIARIES

In October 2001, the Company's subsidiary, Unwire, filed for protection under the bankruptcy courts in Sweden. As a result of the filing the Company has ceased all funding of Unwire operations. The bankruptcy courts have appointed a Trustee to oversee the disbursement of Unwire's assets and the Company now has no control over the operations or decision making capabilities of Unwire. As a result, Unwire is no longer included in the Consolidated financial statements.

The Company's South African subsidiary, CellPoint Systems SA (Pty) Ltd ("Systems SA"), also filed for bankruptcy protection under the laws of South Africa in November 2001. Systems S.A. operated a research and development facility for the Company. The telematics portion of Systems SA had already been recorded within the amounts presented as discontinued operations. The location services portion of Systems SA is not included in discontinued operations, and those functions will continue to be performed by the Company's Swedish subsidiary. Costs of closing this subsidiary, primarily the write-off of the intercompany net receivable from Systems SA, have been accrued in the June 30, 2001 financial statements.

On November 2, 2001 the Company's subsidiary in England, CellPoint Europe Ltd. ("CellPoint Europe"), was filed for liquidation by the appointed liquidator. The functions performed by CellPoint Europe will now be performed by the Swedish subsidiary CellPoint Systems AB and its branch office in the United Kingdom.

The assets, liabilities and results of operations of Systems SA and CellPoint Europe were immaterial to the financial statements of the Company for all periods presented. Included in Financial Items is a gain of \$127,506 related to the reversal of cumulative translation adjustments recorded in prior periods relative to the subsidiaries liquidated other than the portion classified as a discontinued operation (See Notes 2 and 8).

6 SUPPLEMENTAL CASH FLOW INFORMATION

Edgar Filing: CELLPOINT INC - Form 10QSB

	SIX MONTHS ENDED DECEMBER 31, 2001	DECEMBER 2000
Cash paid during the year for:		
Interest related to continuing operations.....	\$389,703	\$104
Interest related to discontinued operations.....	4,796	6
Non-cash transactions relating to investing and financing activities:		
Discount on debt issued.....	1,218,169	2,807
Conversion of convertible debt to common stock.....	450,000	149
Stock subscription receivable	859,292	

7 RESTRICTED CASH

Cash is restricted in accordance with bank performance guarantees whereby in the event the Company does not fulfill certain contracts, the cash will be disbursed to the related customer. The Company has two bank performance guarantees amounting to approximately \$387,000, one of which for approximately \$193,000 expires on December 31, 2004 but will automatically be reduced by approximately \$138,000 on January 1, 2003 and the other for approximately \$194,000 expires on October 30, 2002.

8 FINANCIAL ITEMS, NET

	SIX MONTH ENDED DECEMBER 31, 2001	DECEMBER 2000
Interest income.....	\$ 8,982	\$ 74
Other financial income.....	213,843	85
Interest expense.....	(2,014,576)	(225)
Other financial expense.....	(169,175)	(683)
Realized foreign exchange gains/(loss) (*).....	(324,800)	
Financial items, net.....	(2,285,726)	(748)

(*) Includes a gain of \$127,506 related to cumulative translation adjustments recorded in prior periods relative to foreign subsidiaries now liquidated (See Note 5).

9 DUE TO RELATED PARTY

Bank debt of \$725,750 to finance group operations had been personally guaranteed by certain stockholders of CellPoint Inc. CellPoint Inc. agreed to reimburse these shareholders for amounts paid by these shareholders if the guarantee was called by the bank. These shareholders have agreed to defer the repayment of this amount which the bank claimed in the quarter ended December 31, 2001 until April 15, 2003. The parties further agreed that no interest will be charged. As a result, the amount payable to these shareholders has been classified as a long-term liability in the accompanying financial statements.

Edgar Filing: CELLPOINT INC - Form 10QSB

10 ACCRUED EXPENSES AND OTHER LIABILITIES

	DECEMBER 31, 2001	JUNE 200
Interest expense primarily due October 1, 2002.....	\$ 422,479	\$ 390
Deferred income.....	209,208	
Accrual for a previous acquisition.....	212,176	212
Accrual for contingent costs related to liquidation of subsidiaries.	788,353	
Accrual for normal business expenses.....	1,035,653	1,734
	-----	-----
	\$2,667,869	\$2,337

SIGNATURE

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CELLPOINT INC.

By: /s/ PETER HENRICSSON

Peter Henricsson
President and Chief Executive Officer

By: /s/ LARS WADELL

Lars Wadell
Chief Financial Officer

Date: February 14, 2002